Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Cleveland Clinic
With
Avid Radiopharmaceuticals
F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in myocardium prior to current non-invasive diagnostic measures, particular electrocardiography with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18 florbetapir and assess its correlation between standard non-invasive diagnostic modalities.
Age
18–95
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis
2. Patients with a ratio of affected to unaffected free light chains \>5 or free light chain difference of \>50
You may not be if
1. Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall thickness ≥ 13mm
2. Contraindication to florbetapir or its components
